Get 40% Off
🚨 Markets Are Down. Unlock Undervalued StocksFind Stocks Now

More details emerge from controversial gene-editing experiment in China

Published 11/29/2018, 01:52 PM
Updated 11/29/2018, 01:52 PM
© Reuters.  More details emerge from controversial gene-editing experiment in China
  • In a presentation at the 2nd International Summit on Human Genome Editing in Hong Kong, Chinese researcher He Jiankui said he was "proud" of his achievement and disclosed that a second pregnancy may be on the way.
  • Eight couples undergoing fertility treatments initially enrolled in the trial, but one dropped out. 30 embryos from the remaining seven couples were created and 21 (70%) were edited using CRISPR/Cas9 to knock out the HIV-related gene CCR5.
  • Cord blood from the twin girls, born about a month ago, showed no off-target effects from the gene editing. Both will be followed for 18 years to check for off-target mutations, resistance to HIV and any other potential side effects.
  • He admitted that disabling the CCR5 gene, which is involved immunity, could make the girls more susceptible to infectious diseases but the parents were still in favor of the procedure after being informed of the risks. The father is HIV-positive.
  • Related tickers: (EDIT +2.6%)(CRSP +3.7%)(NTLA +4.1%)
  • Previously: CRISPR Therapeutics up 4% premarket reported use of CRISPR/Cas9 in humans (Nov. 26)
  • Now read: Nektar Currently Misunderstood


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.